GlassScriptPhysician profile
Yeneneh Desta
NPI 1447408562
$1,357.34
in general payments reported to CMS, 2019-2025
12 companies · $442 in 2025
The $442 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.95 · 2021: $11.39 · 2022: $118 · 2023: $120 · 2024: $606 · 2025: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117 · Education: $51.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.45 |
| Education | $51.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $335.27 | 2023-2025 | Nuzyra |
| Organogenesis INC. | $190.54 | 2025 | Nushield, Apligraf, Novachor |
| Kerecis Limited | $178.49 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Surgiclose |
| Smith+Nephew, INC. | $161.84 | 2023-2025 | Grafix Pl, Renasys Touch, Collagenase Santyl |
| Viiv Healthcare Company | $143.95 | 2022-2024 | Dovato |
| Janssen Products, LP | $124.95 | 2019-2022 | |
| Insmed, INC. | $87.15 | 2023-2024 | Arikayce |
| Ets Wound Care LLC | $53.88 | 2024-2025 | Mirragen Advanced Wound Matrix |
| Shionogi INC | $33.60 | 2022 | |
| Next Science LLC | $22.19 | 2024 | Xperience, Blastx, Surgx |
| Mimedx Group, INC. | $14.09 | 2025 | |
| Gilead Sciences, INC. | $11.39 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yeneneh Desta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.